1. Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: protocol design of COVID-HEART-a UK, multicentre, observational study
- Author
-
Gorecka, Miroslawa, McCann, Gerry P., Berry, Colin, Ferreira, Vanessa M., Moon, James, Miller, Christopher A., Chiribiri, Amedeo, Prasad, Sanjay, Dweck, Marc R., Bucciarelli-Ducci, Chiara, Dawson, Dana, Fontana, Marianna, Macfarlane, Peter W., McConnachie, Alex, Neubauer, Stefan, Greenwood, John P., Swoboda, Peter, Steeds, Richard, Fairbairn, Timothy, Flett, Andrew, Green, Thomas, Cole, Graham, McDiarmid, Adam, Bunce, Nicholas, Kanagala, Prathap, Bellenger, Nicholas, Ninan, Tishi, and Alfakih, Khaled
- Subjects
Male ,Contrast Media ,Observation ,Comorbidity ,030204 cardiovascular system & hematology ,030218 nuclear medicine & medical imaging ,Electrocardiography ,Study Protocol ,0302 clinical medicine ,Quality of life ,Risk Factors ,Multicenter Studies as Topic ,myocardial injury ,Myocardial infarction ,Longitudinal Studies ,Prospective Studies ,Prospective cohort study ,Myopericarditis ,Radiological and Ultrasound Technology ,medicine.diagnostic_test ,Myocardial Perfusion Imaging ,Cardiovascular disease ,Troponin ,Myocarditis ,Research Design ,Myocardial repair ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Heart Diseases ,Pneumonia, Viral ,Magnetic Resonance Imaging, Cine ,Walk Test ,03 medical and health sciences ,Myocardial perfusion imaging ,Internal medicine ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Humans ,Radiology, Nuclear Medicine and imaging ,Clinical significance ,Angiology ,business.industry ,SARS-CoV-2 ,COVID-19 ,medicine.disease ,United Kingdom ,Clinical trial ,Coronavirus ,Myocardial inflammation ,RC666-701 ,Quality of Life ,Cardiovascular magnetic resonance ,business ,Biomarkers - Abstract
BackgroundAlthough coronavirus disease 2019 (COVID-19) is primarily a respiratory illness, myocardial injury is increasingly reported and associated with adverse outcomes. However, the pathophysiology, extent of myocardial injury and clinical significance remains unclear.MethodsCOVID-HEART is a UK, multicentre, prospective, observational, longitudinal cohort study of patients with confirmed COVID-19 and elevated troponin (sex-specific > 99th centile). Baseline assessment will be whilst recovering in-hospital or recently discharged, and include cardiovascular magnetic resonance (CMR) imaging, quality of life (QoL) assessments, electrocardiogram (ECG), serum biomarkers and genetics. Assessment at 6-months includes repeat CMR, QoL assessments and 6-min walk test (6MWT). The CMR protocol includes cine imaging, T1/T2 mapping, aortic distensibility, late gadolinium enhancement (LGE), and adenosine stress myocardial perfusion imaging in selected patients. The main objectives of the study are to: (1) characterise the extent and nature of myocardial involvement in COVID-19 patients with an elevated troponin, (2) assess how cardiac involvement and clinical outcome associate with recognised risk factors for mortality (age, sex, ethnicity and comorbidities) and genetic factors, (3) evaluate if differences in myocardial recovery at 6 months are dependent on demographics, genetics and comorbidities, (4) understand the impact of recovery status at 6 months on patient-reported QoL and functional capacity.DiscussionCOVID-HEART will provide detailed characterisation of cardiac involvement, and its repair and recovery in relation to comorbidity, genetics, patient-reported QoL measures and functional capacity.Clinical Trial registration:ISRCTN 58667920. Registered 04 August 2020.
- Published
- 2021